Download PDF
Thromb Haemost 2010; 103(05): 877-883
DOI: 10.1160/TH10-01-0005
Theme Issue Article
Schattauer GmbH

Thrombolysis for pulmonary embolism: Past, present and future

Mareike Lankeit
1   Department of Cardiology and Pulmonology, Georg August University of Göttingen, Göttingen, Germany
,
Stavros Konstantinides
2   Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece
› Author Affiliations
Further Information

Publication History

Received: 04 January 2010

Accepted after minor revision: 22 January 2010

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

Summary

Patients with high-risk pulmonary embolism (PE), i.e. those with shock or hypotension at presentation, are at high risk of in-hospital death, particularly during the first hours after admission. A meta-analysis of trials which included haemodynamically compromised patients indicated that thrombolytic treatment significantly reduces the rate of inhospital death or PE recurrence. Therefore, thrombolysis should be administered to patients with high-risk PE unless there are absolute contraindications to its use. Uncontrolled data further suggest that thrombolysis may be a safe and effective alternative to surgery in patients with PE and free-floating thrombi in the right heart. On the other hand, normotensive patients generally have a favourable short-term prognosis if heparin anticoagulation is instituted promptly, and they are thus considered to have non-high-risk PE. Generally, the bleeding risk of thrombolysis appears to outweigh the clinical benefits of this treatment in patients without haemodynamic compromise. However, within the group of normotensive patients with PE, some may have evidence of right ventricular dysfunction on echocardiography or computed tomography, or of myocardial injury based on elevated cardiac biomarkers (troponin I or T, heart-type fatty acid-binding protein). These patients have an intermediate risk of an adverse outcome in the acute phase of PE. Existing data suggest that selected patients with intermediate-risk PE may benefit from early thrombolytic treatment, particularly if they have a low bleeding risk. However, controversy will continue to surround the optimal treatment for this group until the results of a large ongoing thrombolysis trial are available in a few years.

Keywords

Pulmonary embolism - thrombolysis / thrombolytic agents - plasminogen activators - thrombosis - venous thrombosis
 

  • References

  • 1 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
    CrossrefPubMedGoogle Scholar
  • 2 Anderson Jr. FA, Wheeler HB, Goldberg RJ. et al. A population-based perspective of the hospital incidence and case- fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-938.
    CrossrefPubMedGoogle Scholar
  • 3 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (Suppl. 01) I4-I8.
    PubMedGoogle Scholar
  • 4 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.
    CrossrefPubMedGoogle Scholar
  • 5 Kasper W, Konstantinides S, Geibel A. et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997; 30: 1165-1171.
    CrossrefPubMedGoogle Scholar
  • 6 British Thoracic Society.. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992; 340: 873-876.
    PubMedGoogle Scholar
  • 7 Carson JL, Kelley MA, Duff A. et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245.
    CrossrefPubMedGoogle Scholar
  • 8 Aujesky D, Jimenez D, Mor MK. et al. Weekend versus weekday admission and mortality after acute pulmonary embolism. Circulation 2009; 119: 962-968.
    CrossrefPubMedGoogle Scholar
  • 9 Laporte S, Mismetti P, Decousus H. et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117: 1711-1716.
    CrossrefPubMedGoogle Scholar
  • 10 Office of the Surgeon General.. Acting Surgeon General issues ‘call to action to prevent deep vein thrombosis and pulmonary embolism‘. September 2008. Accessed March 1, 2010 at: http://www.surgeongeneral.gov/news/pressreleases/pr20080915.html
    PubMedGoogle Scholar
  • 11 Cohen AT, Agnelli G, Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Cohen AT, Edmondson RA, Phillips MJ. et al. The changing pattern of venous thromboembolic disease. Haemostasis 1996; 26: 65-71.
    PubMedGoogle Scholar
  • 13 Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991; 302: 709-711.
    CrossrefPubMedGoogle Scholar
  • 14 Kasper W, Konstantinides S, Geibel A. et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77: 346-349.
    CrossrefPubMedGoogle Scholar
  • 15 Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol 2005; 20: 496-501.
    CrossrefPubMedGoogle Scholar
  • 16 Miller RL, Das S, Anandarangam T. et al. Association between right ventricular function and perfusion abnormalities in hemodynamically stable patients with acute pulmonary embolism. Chest 1998; 113: 665-670.
    CrossrefPubMedGoogle Scholar
  • 17 McIntyre KM, Sasahara AA. Determinants of right ventricular function and hemodynamics after pulmonary embolism. Chest 1974; 65: 534-543.
    CrossrefPubMedGoogle Scholar
  • 18 McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol 1971; 28: 288-294.
    CrossrefPubMedGoogle Scholar
  • 19 Greyson C, Xu Y, Cohen J. et al. Right ventricular dysfunction persists following brief right ventricular pressure overload. Cardiovasc Res 1997; 34: 281-288.
    CrossrefPubMedGoogle Scholar
  • 20 Schmitto JD, Doerge H, Post H. et al. Progressive right ventricular failure is not explained by myocardial ischemia in a pig model of right ventricular pressure overload. Eur J Cardiothorac Surg 2009; 35: 229-234.
    CrossrefPubMedGoogle Scholar
  • 21 Chung T, Connor D, Joseph J. et al. Platelet activation in acute pulmonary embolism. J Thromb Haemost 2007; 05: 918-924.
    CrossrefPubMedGoogle Scholar
  • 22 Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc Res 2000; 48: 23-33.
    CrossrefPubMedGoogle Scholar
  • 23 Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med 2008; 359: 2804-2813.
    CrossrefPubMedGoogle Scholar
  • 24 Torbicki A, Perrier A, Konstantinides SV. et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315.
    CrossrefPubMedGoogle Scholar
  • 25 Kucher N, Rossi E, De Rosa M. et al. Massive pulmonary embolism. Circulation 2006; 113: 577-582.
    CrossrefPubMedGoogle Scholar
  • 26 Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108: 978-981.
    CrossrefPubMedGoogle Scholar
  • 27 Grifoni S, Olivotto I, Cecchini P. et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000; 101: 2817-2822.
    CrossrefPubMedGoogle Scholar
  • 28 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 454S-545S.
    CrossrefPubMedGoogle Scholar
  • 29 Miller GA, Sutton GC, Kerr IH. et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Heart J 1971; 33: 616.
    PubMedGoogle Scholar
  • 30 The urokinase pulmonary embolism trial.. A national cooperative study. Circulation 1973; 47 (Suppl. 02) II1-108.
    CrossrefPubMedGoogle Scholar
  • 31 Tibbutt DA, Davies JA, Anderson JA. et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism. Br Med J 1974; 01: 343-347.
    CrossrefPubMedGoogle Scholar
  • 32 Ly B, Arnesen H, Eie H. et al. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203: 465-470.
    PubMedGoogle Scholar
  • 33 Marini C, Di Ricco G, Rossi G. et al. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988; 54: 162-173.
    CrossrefPubMedGoogle Scholar
  • 34 Levine M, Hirsh J, Weitz J. et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-1479.
    CrossrefPubMedGoogle Scholar
  • 35 Tissue plasminogen activator for the treatment of acute pulmonary embolism.. A collaborative study by the PIOPED Investigators. Chest 1990; 97: 528-533.
    CrossrefPubMedGoogle Scholar
  • 36 Dalla-Volta S, Palla A, Santolicandro A. et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992; 20: 520-526.
    CrossrefPubMedGoogle Scholar
  • 37 Goldhaber SZ, Haire WD, Feldstein ML. et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-511.
    CrossrefPubMedGoogle Scholar
  • 38 Meneveau N, Seronde MF, Blonde MC. et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006; 129: 1043-1050.
    CrossrefPubMedGoogle Scholar
  • 39 Daniels LB, Parker JA, Patel SR. et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80: 184-188.
    CrossrefPubMedGoogle Scholar
  • 40 Dalen JE, Banas Jr. JS, Brooks HL. et al. Resolution rate of acute pulmonary embolism in man. N Engl J Med 1969; 280: 1194-1199.
    CrossrefPubMedGoogle Scholar
  • 41 Konstantinides S, Tiede N, Geibel A. et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998; 82: 966-970.
    CrossrefPubMedGoogle Scholar
  • 42 Konstantinides S, Geibel A, Heusel G. et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143-1150.
    CrossrefPubMedGoogle Scholar
  • 43 Kanter DS, Mikkola KM, Patel SR. et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111: 1241-1245.
    CrossrefPubMedGoogle Scholar
  • 44 Sors H, Pacouret G, Azarian R. et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994; 106: 712-717.
    CrossrefPubMedGoogle Scholar
  • 45 Goldhaber SZ, Kessler CM, Heit JA. et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992; 20: 24-30.
    CrossrefPubMedGoogle Scholar
  • 46 Meyer G, Sors H, Charbonnier B. et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism [see comments]. J Am Coll Cardiol 1992; 19: 239-245.
    CrossrefPubMedGoogle Scholar
  • 47 Goldhaber SZ, Kessler CM, Heit J. et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; 02: 293-298.
    PubMedGoogle Scholar
  • 48 Verstraete M, Miller GA, Bounameaux H. et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77: 353-360.
    CrossrefPubMedGoogle Scholar
  • 49 Urokinase-streptokinase embolism trial.. Phase 2 results. A cooperative study. J Am Med Assoc 1974; 229: 1606-1613.
    CrossrefPubMedGoogle Scholar
  • 50 Konstantinides S, Marder VJ. Thrombolysis in venous thromboembolism. In: Hemostasis and Thrombosis. Lippincott Williams and Wilkins; 2006: 1317-1329.
    Google Scholar
  • 51 Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management [see comments]. Ann Intern Med 1994; 121: 313-317.
    CrossrefPubMedGoogle Scholar
  • 52 Hamel E, Pacouret G, Vincentelli D. et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 2001; 120: 120-125.
    CrossrefPubMedGoogle Scholar
  • 53 Meyer G, Gisselbrecht M, Diehl JL. et al. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998; 105: 472-477.
    CrossrefPubMedGoogle Scholar
  • 54 Meneveau N, Schiele F, Metz D. et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998; 31: 1057-1063.
    CrossrefPubMedGoogle Scholar
  • 55 Meneveau N, Schiele F, Vuillemenot A. et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J 1997; 18: 1141-1148.
    CrossrefPubMedGoogle Scholar
  • 56 Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest 1994; 106: 718-724.
    CrossrefPubMedGoogle Scholar
  • 57 Tebbe U, Graf A, Kamke W. et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999; 138: 39-44.
    CrossrefPubMedGoogle Scholar
  • 58 Tebbe U, Bramlage P, Graf A. et al. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost 2009; 101: 557-562.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Becattini C, Agnelli G, Salvi A. et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125: e82-86.
    CrossrefPubMedGoogle Scholar
  • 60 Wan S, Quinlan DJ, Agnelli G. et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110: 744-749.
    CrossrefPubMedGoogle Scholar
  • 61 Eid-Lidt G, Gaspar J, Sandoval J. et al. Combined clot fragmentation and aspiration in patients with acute pulmonary embolism. Chest 2008; 134: 54-60.
    CrossrefPubMedGoogle Scholar
  • 62 Kucher N, Goldhaber SZ. Mechanical catheter intervention in massive pulmonary embolism: proof of concept. Chest 2008; 134: 2-4.
    CrossrefPubMedGoogle Scholar
  • 63 Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest 2002; 121: 806-814.
    CrossrefPubMedGoogle Scholar
  • 64 Chartier L, Bera J, Delomez M. et al. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients. Circulation 1999; 99: 2779-2783.
    CrossrefPubMedGoogle Scholar
  • 65 Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 2005; 112: e28-e32.
    CrossrefPubMedGoogle Scholar
  • 66 Ribeiro A, Lindmarker P, Juhlin-Dannfelt A. et al. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997; 134: 479-487.
    CrossrefPubMedGoogle Scholar
  • 67 Kucher N, Rossi E, De Rosa M. et al. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 2005; 165: 1777-1781.
    CrossrefPubMedGoogle Scholar
  • 68 ten Wolde M, Sohne M, Quak E. et al. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004; 164: 1685-1689.
    CrossrefPubMedGoogle Scholar
  • 69 Sanchez O, Trinquart L, Colombet I. et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008; 29: 1569-1577.
    CrossrefPubMedGoogle Scholar
  • 70 Binder L, Pieske B, Olschewski M. et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005; 112: 1573-1579.
    CrossrefPubMedGoogle Scholar
  • 71 Sanchez O, Trinquart L, Caille V. et al. Prognostic Factors for Pulmonary Embolism: The PREP Study, A Prospective Multicenter Cohort Study. Am J Respir Crit Care Med 2010; 181: 168-173.
    CrossrefPubMedGoogle Scholar
  • 72 Schoepf UJ, Kucher N, Kipfmueller F. et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004; 110: 3276-3280.
    CrossrefPubMedGoogle Scholar
  • 73 Kucher N, Printzen G, Doernhoefer T. et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107: 1576-1578.
    CrossrefPubMedGoogle Scholar
  • 74 Kucher N, Printzen G, Goldhaber SZ. Prognostic Role of Brain Natriuretic Peptide in Acute Pulmonary Embolism. Circulation 2003; 107: 2545.
    CrossrefPubMedGoogle Scholar
  • 75 Pruszczyk P, Kostrubiec M, Bochowicz A. et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003; 22: 649-653.
    CrossrefPubMedGoogle Scholar
  • 76 ten Wolde M, Tulevski II, Mulder JW. et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107: 2082-2084.
    CrossrefPubMedGoogle Scholar
  • 77 Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003; 108: 2191-2194.
    CrossrefPubMedGoogle Scholar
  • 78 Giannitsis E, Katus HA. Risk stratification in pulmonary embolism based on biomarkers and echocardiography. Circulation 2005; 112: 1520-1521.
    CrossrefPubMedGoogle Scholar
  • 79 Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178: 425-430.
    CrossrefPubMedGoogle Scholar
  • 80 Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006; 92: 987-993.
    CrossrefPubMedGoogle Scholar
  • 81 Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007; 116: 427-433.
    CrossrefPubMedGoogle Scholar
  • 82 Jimenez D, Uresandi F, Otero R. et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and meta-analysis. Chest 2009; 136: 974-982.
    CrossrefPubMedGoogle Scholar
  • 83 Lankeit M, Konstantinides S. Tenecteplase can be given to patients with intermediate-risk pulmonary embolism – But should it?. Thromb Res. 2009; Epub ahead of press.
    PubMedGoogle Scholar
  • 84 Storch J, Thumser AE. The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta 2000; 1486: 28-44.
    CrossrefPubMedGoogle Scholar
  • 85 Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 2004; 97: 187-198.
    CrossrefPubMedGoogle Scholar
  • 86 Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005; 352: 15-35.
    CrossrefPubMedGoogle Scholar
  • 87 Puls M, Dellas C, Lankeit M. et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007; 28: 224-229.
    PubMedGoogle Scholar
  • 88 Kaczynska A, Pelsers MM, Bochowicz A. et al. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clin Chim Acta 2006; 371: 117-123.
    CrossrefPubMedGoogle Scholar
  • 89 Dellas C, Puls M, Lankeit M. et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol. 2010 in press.
    PubMedGoogle Scholar
  • 90 Lankeit M, Kempf T, Dellas C. et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008; 177: 1018-1025.
    CrossrefPubMedGoogle Scholar
  • 91 Lankeit M, Konstantinides S. Thrombolysis for hemodynamically stable patients with pulmonary embolism: still searching for the intermediate-risk group. Thromb Res 2009; 124: 647-648.
    CrossrefPubMedGoogle Scholar